Structural studies with novel ruthenium anticancer agents.

In this study, we aim to obtain the crystal structure of the ruthenium based anticancer agents which will provide us a better understand on the drug’s mechanism of action. Two ruthenium based drugs, RuCl2(η6-p-cymene)-(PTA), (PTA = 1,3,5-triaza-7-phosphaadamantane) or RAPTA-C and Hind[trans-RuCl4(in...

Full description

Bibliographic Details
Main Author: Soon, Cin Huang.
Other Authors: Curtis Alexander Davey
Format: Final Year Project (FYP)
Language:English
Published: 2010
Subjects:
Online Access:http://hdl.handle.net/10356/39540
_version_ 1811684727618273280
author Soon, Cin Huang.
author2 Curtis Alexander Davey
author_facet Curtis Alexander Davey
Soon, Cin Huang.
author_sort Soon, Cin Huang.
collection NTU
description In this study, we aim to obtain the crystal structure of the ruthenium based anticancer agents which will provide us a better understand on the drug’s mechanism of action. Two ruthenium based drugs, RuCl2(η6-p-cymene)-(PTA), (PTA = 1,3,5-triaza-7-phosphaadamantane) or RAPTA-C and Hind[trans-RuCl4(ind)2] (ind = indazole) or KP1019 were chosen to react with different DNA oligonucleotides. Weak non-covalent binding of RAPTA-C towards the DNA oligonucleotides is observed. KP1019 shows a tendency for stronger covalent binding towards the DNA oligonucleotides but requires high drug to DNA molar ratios. Due to its transient binding, RAPTA-C is not suitable for use in crystallizations. Crystals of the KP1019 adducted oligonucleotides could not be obtained from the condition that gave crystals for unadducted oligonucleotides. Hence, more screens are needed to obtain optimized conditions for the growth of KP1019-derivirtized oligonucleotides.
first_indexed 2024-10-01T04:33:14Z
format Final Year Project (FYP)
id ntu-10356/39540
institution Nanyang Technological University
language English
last_indexed 2024-10-01T04:33:14Z
publishDate 2010
record_format dspace
spelling ntu-10356/395402023-02-28T18:01:20Z Structural studies with novel ruthenium anticancer agents. Soon, Cin Huang. Curtis Alexander Davey School of Biological Sciences BioSciences Research Centre DRNTU::Science::Biological sciences::Biochemistry In this study, we aim to obtain the crystal structure of the ruthenium based anticancer agents which will provide us a better understand on the drug’s mechanism of action. Two ruthenium based drugs, RuCl2(η6-p-cymene)-(PTA), (PTA = 1,3,5-triaza-7-phosphaadamantane) or RAPTA-C and Hind[trans-RuCl4(ind)2] (ind = indazole) or KP1019 were chosen to react with different DNA oligonucleotides. Weak non-covalent binding of RAPTA-C towards the DNA oligonucleotides is observed. KP1019 shows a tendency for stronger covalent binding towards the DNA oligonucleotides but requires high drug to DNA molar ratios. Due to its transient binding, RAPTA-C is not suitable for use in crystallizations. Crystals of the KP1019 adducted oligonucleotides could not be obtained from the condition that gave crystals for unadducted oligonucleotides. Hence, more screens are needed to obtain optimized conditions for the growth of KP1019-derivirtized oligonucleotides. Bachelor of Science in Biological Sciences 2010-05-31T02:05:46Z 2010-05-31T02:05:46Z 2010 2010 Final Year Project (FYP) http://hdl.handle.net/10356/39540 en Nanyang Technological University 31 p. application/pdf
spellingShingle DRNTU::Science::Biological sciences::Biochemistry
Soon, Cin Huang.
Structural studies with novel ruthenium anticancer agents.
title Structural studies with novel ruthenium anticancer agents.
title_full Structural studies with novel ruthenium anticancer agents.
title_fullStr Structural studies with novel ruthenium anticancer agents.
title_full_unstemmed Structural studies with novel ruthenium anticancer agents.
title_short Structural studies with novel ruthenium anticancer agents.
title_sort structural studies with novel ruthenium anticancer agents
topic DRNTU::Science::Biological sciences::Biochemistry
url http://hdl.handle.net/10356/39540
work_keys_str_mv AT sooncinhuang structuralstudieswithnovelrutheniumanticanceragents